CL2014001865A1 - Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. - Google Patents

Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.

Info

Publication number: CL2014001865A1
Authority: CL; Chile
Prior art keywords: cancer; treatment; pharmaceutical compositions; compositions containing; preparation procedure
Prior art date: 2013-07-23

Application number

CL2014001865A

Other languages

English (en)

Inventor

Tiran Arnaud Le

Diguarher Thierry Le

Jerome-Benoit Starck

Jean-Michel Henlin

Anne-Francoise Guillouzic

Nanteuil Guillaume De

Olivier Geneste

James Edward Paul Davidson

I-Jen Chen

James Broke Murray

Original Assignee

Servier Lab

Vernalis R&D Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-23

Filing date

2014-07-15

Publication date

2015-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001865(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-15 Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab

2015-06-26 Publication of CL2014001865A1 publication Critical patent/CL2014001865A1/es

Links

206010028980 Neoplasm Diseases 0.000 title 1
229910019142 PO4 Inorganic materials 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
239000010452 phosphate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CL2014001865A 2013-07-23 2014-07-15 Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. CL2014001865A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1357259A FR3008979B1 (fr)	2013-07-23	2013-07-23	Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
CL2014001865A1 true CL2014001865A1 (es)	2015-06-26

Family

ID=50288170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001865A CL2014001865A1 (es)	2013-07-23	2014-07-15	Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.

Country Status (48)

Country	Link
US (3)	US9115159B2 (es)
EP (1)	EP2829545B1 (es)
JP (1)	JP5894638B2 (es)
KR (2)	KR101713103B1 (es)
CN (1)	CN104341451B (es)
AP (1)	AP2014007773A0 (es)
AR (1)	AR097008A1 (es)
AU (1)	AU2014203808B2 (es)
BR (1)	BR102014017997B1 (es)
CA (1)	CA2856886C (es)
CL (1)	CL2014001865A1 (es)
CR (1)	CR20140336A (es)
CU (1)	CU24316B1 (es)
CY (1)	CY1117834T1 (es)
DK (1)	DK2829545T3 (es)
DO (1)	DOP2014000163A (es)
EA (1)	EA027444B1 (es)
EC (1)	ECSP14008757A (es)
ES (1)	ES2593417T3 (es)
FR (1)	FR3008979B1 (es)
GE (1)	GEP201706704B (es)
HK (2)	HK1201536A1 (es)
HR (1)	HRP20161202T8 (es)
HU (1)	HUE029616T2 (es)
IL (1)	IL233580B (es)
JO (1)	JO3160B1 (es)
MA (1)	MA37213B1 (es)
MD (1)	MD4551C1 (es)
ME (1)	ME02641B (es)
MX (1)	MX351467B (es)
MY (1)	MY173258A (es)
NI (1)	NI201400080A (es)
PE (1)	PE20150218A1 (es)
PH (1)	PH12014000194B1 (es)
PL (1)	PL2829545T3 (es)
PT (1)	PT2829545T (es)
RS (1)	RS55098B1 (es)
RU (1)	RU2617682C2 (es)
SA (1)	SA114350669B1 (es)
SG (1)	SG10201403939WA (es)
SI (1)	SI2829545T1 (es)
SV (1)	SV2014004771A (es)
TN (1)	TN2014000301A1 (es)
TW (1)	TWI527824B (es)
UA (1)	UA119738C2 (es)
UY (1)	UY35661A (es)
WO (1)	WO2015011399A1 (es)
ZA (1)	ZA201405418B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008977A1 (fr) *	2013-07-23	2015-01-30	Servier Lab	Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) *	2013-07-23	2015-01-30	Servier Lab	"nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
UY37316A (es) *	2016-07-07	2018-01-31	Servier Lab	Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
AU2017300738A1 (en)	2016-07-22	2019-02-07	Les Laboratoires Servier	Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
MA45718A (fr) *	2016-07-22	2019-05-29	Servier Lab	Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
WO2018158225A1 (en)	2017-02-28	2018-09-07	Les Laboratoires Servier	Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) *	2017-06-09	2022-02-17	Ле Лаборатуар Сервье	Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
AR112440A1 (es) *	2017-07-06	2019-10-30	Servier Lab	Forma cristalina de un inhibidor de bcl-2, un proceso para su preparación y composiciones farmacéuticas que la contienen
FR3072679B1 (fr) *	2017-10-25	2020-10-30	Servier Lab	Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2019215081B2 (en)	2018-01-31	2024-07-25	Deciphera Pharmaceuticals, Llc.	Combination therapy for the treatment of gastrointestinal stromal tumors
JP7523351B2 (ja)	2018-01-31	2024-07-26	デシフェラ・ファーマシューティカルズ，エルエルシー	肥満細胞症の治療のための併用療法
CN114615982A (zh)	2019-08-12	2022-06-10	德西费拉制药有限责任公司	用于治疗胃肠道间质瘤的瑞普替尼
TW202122082A (zh)	2019-08-12	2021-06-16	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
CN110606860B (zh) *	2019-09-29	2021-12-10	上海勋和医药科技有限公司	一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
MX2022008097A (es)	2019-12-30	2022-09-19	Deciphera Pharmaceuticals Llc	Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dih idro-1,6-naftiridin-3-yl)-2-fluorofeil)-3-fenilurea.
MX2022008103A (es)	2019-12-30	2022-09-19	Deciphera Pharmaceuticals Llc	Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
BR112023017344A2 (pt) *	2021-03-12	2023-09-26	Eil Therapeutics Inc	Compostos que têm tetra-hidroindolizina-1-carboxamida como inibidores de bcl-2
EP4413000A1 (en)	2021-10-04	2024-08-14	FoRx Therapeutics AG	N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
AR129380A1 (es)	2022-05-20	2024-08-21	Novartis Ag	Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2484209C (en) *	2002-05-03	2013-06-11	Exelixis, Inc.	Protein kinase modulators and methods of use
WO2004004727A1 (en) *	2002-07-03	2004-01-15	Axys Pharmaceuticals, Inc.	3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) *	2002-10-22	2002-11-27	Glaxo Group Ltd	Novel compounds
BRPI0620151A2 (pt) *	2005-12-22	2010-06-29	Wyeth Corp	composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
US7902218B2 (en)	2006-12-12	2011-03-08	Bristol-Myers Squibb Company	Substituted tetrahydroisoquinolines as β-secretase inhibitors
MY162157A (en) *	2007-04-16	2017-05-31	Abbott Lab	Substituted indole mcl-1 inhibitors
US8263607B2 (en)	2007-05-22	2012-09-11	Astellas Pharma Inc.	1-substituted tetrahydroisoquinoline compound
NZ587039A (en) *	2008-02-13	2013-01-25	Gilead Connecticut Inc	6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
RU2525116C2 (ru) *	2008-12-19	2014-08-10	Дженентек, Инк.	Гетероциклические соединения и способы применения
TWI520960B (zh) *	2010-05-26	2016-02-11	艾伯維有限公司	用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en)	2011-05-23	2012-11-29	Senko Advanced Components, Inc.	True one piece housing fiber optic adapter
WO2013096059A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
US20140357666A1 (en)	2011-12-23	2014-12-04	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140107578A (ko)	2011-12-23	2014-09-04	노파르티스 아게	Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
MX2014007729A (es)	2011-12-23	2015-01-12	Novartis Ag	Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
BR112014015339A8 (pt)	2011-12-23	2017-06-13	Novartis Ag	compostos para inibição da interação de bcl2 com parceiros de ligação
CN103177906A (zh)	2011-12-26	2013-06-26	西门子公司	用于中压开关设备的断路器
ITPR20110103A1 (it)	2011-12-27	2013-06-28	G E A F S R L	Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en)	2011-12-29	2015-08-25	Inventio Ag	Emergency operation of elevators based on an indicated emergency condition
FR2986002B1 (fr) *	2012-01-24	2014-02-21	Servier Lab	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IN2012DE00210A (es)	2012-01-24	2015-06-19	Danfoss As

2013
- 2013-07-23 FR FR1357259A patent/FR3008979B1/fr active Active
2014
- 2014-07-08 PH PH12014000194A patent/PH12014000194B1/en unknown
- 2014-07-09 SG SG10201403939WA patent/SG10201403939WA/en unknown
- 2014-07-09 AP AP2014007773A patent/AP2014007773A0/xx unknown
- 2014-07-09 JO JOP/2014/0222A patent/JO3160B1/ar active
- 2014-07-10 MY MYPI2014701887A patent/MY173258A/en unknown
- 2014-07-10 PE PE2014001093A patent/PE20150218A1/es active IP Right Grant
- 2014-07-10 EC ECIEPI20148757A patent/ECSP14008757A/es unknown
- 2014-07-10 IL IL233580A patent/IL233580B/en active IP Right Grant
- 2014-07-11 AU AU2014203808A patent/AU2014203808B2/en active Active
- 2014-07-11 UY UY35661A patent/UY35661A/es unknown
- 2014-07-11 CR CR20140336A patent/CR20140336A/es unknown
- 2014-07-11 TN TNP2014000301A patent/TN2014000301A1/fr unknown
- 2014-07-14 CA CA2856886A patent/CA2856886C/fr active Active
- 2014-07-15 MA MA37213A patent/MA37213B1/fr unknown
- 2014-07-15 CL CL2014001865A patent/CL2014001865A1/es unknown
- 2014-07-15 MD MDA20140073A patent/MD4551C1/ro not_active IP Right Cessation
- 2014-07-15 DO DO2014000163A patent/DOP2014000163A/es unknown
- 2014-07-17 UA UAA201408109A patent/UA119738C2/uk unknown
- 2014-07-17 SV SV2014004771A patent/SV2014004771A/es unknown
- 2014-07-21 GE GEAP201413528A patent/GEP201706704B/en unknown
- 2014-07-22 PT PT141780304T patent/PT2829545T/pt unknown
- 2014-07-22 TW TW103125160A patent/TWI527824B/zh not_active IP Right Cessation
- 2014-07-22 ME MEP-2016-208A patent/ME02641B/me unknown
- 2014-07-22 BR BR102014017997A patent/BR102014017997B1/pt active IP Right Grant
- 2014-07-22 EA EA201400754A patent/EA027444B1/ru unknown
- 2014-07-22 ES ES14178030.4T patent/ES2593417T3/es active Active
- 2014-07-22 AR ARP140102712A patent/AR097008A1/es unknown
- 2014-07-22 DK DK14178030.4T patent/DK2829545T3/en active
- 2014-07-22 PL PL14178030.4T patent/PL2829545T3/pl unknown
- 2014-07-22 WO PCT/FR2014/051887 patent/WO2015011399A1/fr active Application Filing
- 2014-07-22 SI SI201430059A patent/SI2829545T1/sl unknown
- 2014-07-22 HU HUE14178030A patent/HUE029616T2/en unknown
- 2014-07-22 EP EP14178030.4A patent/EP2829545B1/fr active Active
- 2014-07-22 RS RS20160693A patent/RS55098B1/sr unknown
- 2014-07-22 RU RU2014130129A patent/RU2617682C2/ru active
- 2014-07-22 NI NI201400080A patent/NI201400080A/es unknown
- 2014-07-22 MX MX2014008866A patent/MX351467B/es active IP Right Grant
- 2014-07-22 JP JP2014148946A patent/JP5894638B2/ja active Active
- 2014-07-22 ZA ZA2014/05418A patent/ZA201405418B/en unknown
- 2014-07-22 SA SA114350669A patent/SA114350669B1/ar unknown
- 2014-07-22 US US14/337,577 patent/US9115159B2/en active Active
- 2014-07-23 KR KR1020140093393A patent/KR101713103B1/ko active IP Right Grant
- 2014-07-23 CN CN201410354089.1A patent/CN104341451B/zh active Active
- 2014-07-23 CU CUP2014000095A patent/CU24316B1/es unknown
2015
- 2015-03-02 HK HK15102098.0A patent/HK1201536A1/zh not_active IP Right Cessation
- 2015-06-01 HK HK15105213.3A patent/HK1204623A1/xx unknown
- 2015-07-16 US US14/800,871 patent/US9597341B2/en active Active
2016
- 2016-07-18 CY CY20161100696T patent/CY1117834T1/el unknown
- 2016-09-20 HR HRP20161202TT patent/HRP20161202T8/hr unknown
- 2016-12-23 KR KR1020160177980A patent/KR20170001694A/ko not_active Application Discontinuation
2017
- 2017-02-06 US US15/425,119 patent/US20170143746A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20170001694A (ko)	2017-01-04
MA37213B1 (fr)	2017-03-31
US20170143746A1 (en)	2017-05-25
EA201400754A2 (ru)	2014-12-30
DOP2014000163A (es)	2015-01-15
PH12014000194A1 (en)	2015-06-29
AR097008A1 (es)	2016-02-10
ME02641B (me)	2017-06-20
CU20140095A7 (es)	2016-02-29
HRP20161202T1 (hr)	2016-11-04
SI2829545T1 (sl)	2016-10-28
ECSP14008757A (es)	2016-01-29
RU2014130129A (ru)	2016-02-10
CA2856886A1 (fr)	2015-01-23
TN2014000301A1 (fr)	2015-12-21
EP2829545A1 (fr)	2015-01-28
JO3160B1 (ar)	2017-09-20
PT2829545T (pt)	2016-07-13
CR20140336A (es)	2015-10-07
SG10201403939WA (en)	2015-02-27
UA119738C2 (uk)	2019-08-12
NZ627178A (en)	2016-01-29
AU2014203808B2 (en)	2018-09-20
IL233580A0 (en)	2014-11-02
MY173258A (en)	2020-01-09
MX351467B (es)	2017-10-17
PL2829545T3 (pl)	2016-12-30
TW201504254A (zh)	2015-02-01
UY35661A (es)	2015-02-27
BR102014017997A2 (pt)	2015-11-17
GEP201706704B (en)	2017-07-25
EP2829545B1 (fr)	2016-06-22
JP2015028017A (ja)	2015-02-12
ZA201405418B (en)	2020-02-26
HK1201536A1 (zh)	2015-09-04
HUE029616T2 (en)	2017-03-28
EA027444B1 (ru)	2017-07-31
MX2014008866A (es)	2015-07-21
MA37213A1 (fr)	2016-06-30
NI201400080A (es)	2014-10-24
JP5894638B2 (ja)	2016-03-30
MD4551B1 (ro)	2018-02-28
CU24316B1 (es)	2018-02-08
US20150313923A1 (en)	2015-11-05
SV2014004771A (es)	2015-01-28
AU2014203808A1 (en)	2015-02-12
IL233580B (en)	2020-03-31
HK1204623A1 (en)	2015-11-27
BR102014017997B1 (pt)	2020-05-19
US20150031648A1 (en)	2015-01-29
KR20150011785A (ko)	2015-02-02
CA2856886C (fr)	2016-08-02
CN104341451B (zh)	2018-04-03
MD4551C1 (ro)	2018-09-30
US9597341B2 (en)	2017-03-21
AP2014007773A0 (en)	2014-07-31
SA114350669B1 (ar)	2016-04-11
US9115159B2 (en)	2015-08-25
ES2593417T3 (es)	2016-12-09
PE20150218A1 (es)	2015-02-14
HRP20161202T8 (hr)	2016-12-30
MD20140073A2 (en)	2015-01-31
DK2829545T3 (en)	2016-09-19
CY1117834T1 (el)	2017-05-17
EA201400754A3 (ru)	2015-03-31
WO2015011399A1 (fr)	2015-01-29
RU2617682C2 (ru)	2017-04-26
FR3008979B1 (fr)	2015-07-24
FR3008979A1 (fr)	2015-01-30
CN104341451A (zh)	2015-02-11
RS55098B1 (sr)	2016-12-30
TWI527824B (zh)	2016-04-01
KR101713103B1 (ko)	2017-03-07
PH12014000194B1 (en)	2015-06-29

Publication	Publication Date	Title
CL2014001865A1 (es)	2015-06-26	Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2014001829A1 (es)	2015-01-02	Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014003444A1 (es)	2015-10-23	Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CO2017001994A2 (es)	2017-05-19	Compuestos activos hacia bromodominios
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2016000807A1 (es)	2016-07-08	Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016000153A1 (es)	2016-07-29	Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
PH12019500176A1 (en)	2020-11-04	Heterocyclic compounds and ther uses
CL2015003395A1 (es)	2016-05-20	Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2016001604A1 (es)	2017-05-26	“compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2015001985A1 (es)	2015-10-02	Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2013003019A1 (es)	2014-02-14	Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2013002517A1 (es)	2014-07-25	Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2016001609A1 (es)	2016-12-09	Composiciones farmacéuticas que comprenden azd9291.
ECSP15026557A (es)	2016-01-29	Compuestos y sus métodos de empleo
CL2013002898A1 (es)	2014-08-22	Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2014001853A1 (es)	2015-06-26	Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
CL2014002358A1 (es)	2015-04-24	Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015002767A1 (es)	2016-12-30	Compuestos terapéuticos y composiciones
IL258246B (en)	2021-10-31	Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
CL2016000063A1 (es)	2016-08-19	Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.